Effectiveness of a fixed-ratio combination of insulin degludec/liraglutide (IDegLira) for Treating 1499 Chinese Type 2 Diabetes Patients: A Real-World Prospective Observational Study

The use and effectiveness of Tegu insulin Liraglutide injection (IDegLira) in a real-world population with type 2 diabetes: results from a cross-sectional study in China

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2500096325

Enrollment

Unknown

Registered

2025-01-21

Start date

2023-06-01

Completion date

Unknown

Last updated

2025-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes mellitus

Interventions

OAD:IDegLira

Basal:IDegLira

B+B:IDegLira

Basal+GLP-1RA:IDegLira

GLP-1RA:IDegLira

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Meet the 1999 WHO diagnostic criteria for diabetes type 1 or type 2 diabetes or have a clear history of type 1 or type 2 diabetes 2) Aged 18-80; 3) Have received at least one IDegLira prescription.

Exclusion criteria

Exclusion criteria: Is currently participating in or has completed another clinical trial within 3 months; Or they were positive for chorionic gonadotropin or were unable to use contraception during the study period.

Design outcomes

Primary

Measure	Time frame
HbA1c;Dose;	—

Secondary

Measure	Time frame
Fasting blood glucose;Weight;	—

Countries

China

Contacts

Public ContactJie Zhang

Beijing Hospital

18611407002@163.com+86 186 1140 7002

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026